Market Overview

According to fortune business insights, the global pen needles market size was valued at USD 2.41 billion in 2025. The market is projected to grow from USD 2.56 billion in 2026 to USD 4.58 billion by 2034, exhibiting a CAGR of 7.50% during the forecast period. North America dominated the pen needles market with a market share of 39.60% in 2025.

The analysis shows that the increasing prevalence of diseases such as diabetes, osteoporosis, and growth hormone deficiency, coupled with the increased usage of injection pens for drug delivery, is driving market growth. For instance, Ypsomed reported in November 2023 that sales of its UnoPen and YpsoPen injections exceeded 100 million and 10 million units, respectively, indicating strong demand.

Major Players Profiled in the Market Report:

• Novo Nordisk A/S (Denmark)
• Embecta Corp. (U.S.)
• B. Braun SE (Germany)
• Owen Mumford (U.K.)
• BD (U.S.)
• Cardinal Health (U.S.)
• SOL-Millennium (U.S.)
• Terumo Corporation (Japan)
• MTD Medical Technology and Devices S.p.A. (Italy)
• UltiMed, Inc. (U.S.)
• Allison Medical, Inc. (U.S.)

Segments

Increasing Prevalence of Diseases to Fuel Demand for Standard Pen Needles

By product type, the market is segmented into standard pen needles and safety pen needles. The standard pen needles segment is projected to hold the largest market share (67.97% in 2026) due to the high prevalence of diseases like diabetes and less awareness regarding needlestick injuries.

Growing Demand for Insulin Pens to Drive Insulin Segment Growth

Based on drug type, the market is divided into insulin, GLP-1, growth hormone, and others. The insulin segment is expected to dominate, accounting for a 75.39% market share in 2026, driven by strong demand for insulin in diabetes management.